AMRX

Amneal Pharmaceuticals, Inc. AMRX

NasdaqMid CapHealthcare

13F Pro quality score

Rank #1,023 of 2,925TOP 50%

Why it scores 58Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$796.20M

Quarter to Jun 30

Net income

$57.66M

Quarter to Jun 30

Free cash flow

$-51.94M

Quarter to Jun 30

Operating margin

16.3%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.82B total
BlackRock, Inc.
$459.79M+8.3%
TPG GP A, LLC
$213.41M0.0%
VANGUARD PORTFOLIO MANAGEMENT LLC
$210.10M+7.2%
Rubric Capital Management LP
$176.02M-7.9%
VANGUARD CAPITAL MANAGEMENT LLC
$133.46M+1.6%
STATE STREET CORP
$127.35M+8.3%
DIMENSIONAL FUND ADVISORS LP
$100.30M+1.8%
GEODE CAPITAL MANAGEMENT, LLC
$88.98M+13.1%
MORGAN STANLEY
$71.14M-11.4%
Neuberger Berman Group LLC
$67.28M+5.6%
Invesco Ltd.
$60.62M+9.8%
Nuveen, LLC
$57.55M+2.5%
Allspring Global Investments Holdings, LLC
$55.93M+29.3%
GOLDMAN SACHS GROUP INC
$52.17M+5.2%
Assenagon Asset Management S.A.
$42.33M-20.3%
Nantahala Capital Management, LLC
$39.27M-20.2%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$37.17M-1.7%
NORTHERN TRUST CORP
$33.15M+12.2%
ACADIAN ASSET MANAGEMENT LLC
$28.55M-14.6%
AMERIPRISE FINANCIAL INC
$27.39M-15.2%
Westshore Wealth, LLC
$23.65M-0.6%
BlackBarn Capital Partners LP
$22.50M-21.2%
Penn Capital Management Company, LLC
$20.48M-1.2%
VANGUARD FIDUCIARY TRUST CO
$20.24M+1.3%
CITADEL ADVISORS LLC
$19.36M+93.7%
See all 312 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AMRX

Earnings Per Share

13fpro.ai/company/AMRX

Loading ratio trend…

Companies similar to AMRX

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

AMRX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Amneal Pharmaceuticals, Inc. (AMRX): stock profile, AI score and financials

Amneal Pharmaceuticals, Inc. (AMRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMRX at 58.3/100 on a composite quality score built from its SEC filings, placing it at rank #1,023 of 2,925 stocks — the top half of the AI-ranked universe. Areas of concern include institutional flow (36.4) and free cash flow (39.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Amneal Pharmaceuticals, Inc. reports quarterly revenue of $796.2M, net income of $57.7M, an operating margin of 16.3%. AMRX trades on the Nasdaq exchange and files with the SEC under CIK 1723128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amneal Pharmaceuticals, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1723128 →